Arcus Biosciences, Inc.
Arcus Biosciences, Inc. (NYSE: RCUS) is a clinical-stage biopharmaceutical company developing medicines for cancer and inflammatory and autoimmune diseases. Its oncology pipeline includes casdatifan, a small-molecule HIF-2α inhibitor; quemliclustat, a CD73 inhibitor; domvanalimab, an anti-TIGIT antibody; and… From the company’s description.
Over the twelve months to Sep 30, 2026, Arcus Biosciences, Inc. reported revenue of $100.00M, down 58.3% from a year earlier, and a net loss of $453.00M. Its operating margin was −475.0%, and operations used $465.00M in cash. In fiscal 2025, it reported revenue of $247.00M, down 4.3% from fiscal 2024, and a net loss of $353.00M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Arcus Biosciences, Inc. does
In the company’s own words
Arcus Biosciences, Inc. (NYSE: RCUS) is a clinical-stage biopharmaceutical company developing medicines for cancer and inflammatory and autoimmune diseases. Its oncology pipeline includes casdatifan, a small-molecule HIF-2α inhibitor; quemliclustat, a CD73 inhibitor; domvanalimab, an anti-TIGIT antibody; and zimberelimab, an anti-PD-1 antibody. The company is also advancing small-molecule programs in inflammation, including research targeting MRGPRX2, TNF, CCR6, CD89 and CD40 ligand, with a focus on oral therapies. Arcus has no reportable business segments described here; it works with Gilead Sciences on development and commercialization of certain oncology programs and has licensed regional rights to Taiho Pharmaceutical. Its most advanced molecules are in Phase 3 studies, including casdatifan for renal cell carcinoma and quemliclustat for metastatic pancreatic cancer. Arcus reports no product sales and relies on third parties to manufacture its investigational medicines. Its website is www.arcusbio.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- HAYWARD, CA
- Fiscal year end
- December
- CIK
- 1724521
- SIC
- 2834
Financial performance, year by year
Fiscal 2018–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Arcus Biosciences, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Arcus Biosciences, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Arcus Biosciences, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Arcus Biosciences, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Arcus Biosciences, Inc.'s last four quarterly filings that the numbers alone won't show?”